Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Royal DSM N.V.
  6. News
  7. Summary
    DSM   NL0000009827

ROYAL DSM N.V.

(DSM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royal DSM and Brains Bioceutical Form Exclusive Global Partnership to Unlock the Therapeutic Potential of Cannabinoids in Early-Stage Drug Development

06/23/2021 | 06:00am EDT

Royal DSM announced it has entered into an exclusive commercial partnership with global leader and pioneer in cannabinoid active pharmaceutical ingredients (APIs), Brains Bioceutical. The partnership extends DSM's capabilities as a purpose-led innovation partner in the pharmaceutical market – creating a platform from which it can enable agile early-stage drug development to unlock and deliver value-added cannabinoid-based products that benefit global patient health. Together, DSM and Brains Bioceutical are strategically positioned to lead the development of cannabinoid based pharmaceutical products, using Brains' EU-GMP APIs. The cannabinoid API market is fast-growing, powered by strong scientific evidence demonstrating the potential of cannabinoid in several therapeutic areas, including Central Nervous System (CNS) diseases. CNS diseases – a broad category of neurological conditions including epilepsy, Alzheimer's disease, Parkinson's disease, and stroke – are increasingly recognized as one of the most prevalent disorders worldwide with a high burden to patients. With positive findings in more than 160 clinical trials to date, there is an opportunity to create a new platform that will support pharmaceutical manufacturers in the development of bespoke cannabinoid-based drug products that expand treatment possibilities. Enabled by Brains Bioceutical's leading portfolio of naturally-sourced, EU-GMP cannabinoid APIs – registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and with a filed Drug Master File (DMF) with the Food and Drug Administration (FDA) in the USA - and extensive expertise in the sector, the partnership will see DSM apply its science and marketing capabilities to bring the highest quality cannabinoid APIs to customers, with the capability to manufacture custom cannabinoids. This will create new innovation opportunities for prescription drug (Rx) manufacturers and enable them to enter the cannabinoid market with confidence. Brains Bioceutical is the ideal partner due to its extensive EU-GMP certified cannabinoid manufacturing capabilities and unparalleled expertise in the cannabis and hemp sectors. As one of the only companies worldwide to provide a secure supply of standardized API cannabinoids of natural origin, Brains Bioceutical is setting the global standard for cannabinoid API innovation. The investment and strategic transaction solidify the position of Brains Bioceutical as one of the leading pharmaceutical companies in the CBD sector and will allow it to take advantage of strategic partnerships that DSM has developed.


ę S&P Capital IQ 2021
All news about ROYAL DSM N.V.
09/14DSM Starts A Review of Strategic Options
CI
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM accelerates its strategic journey to a..
PU
09/14Europe ends flat as miners, luxury stocks weigh; inflation optimism cools
RE
09/14ROYAL DSM N : Koninklijke DSM N.V., - DSM announces food system commitments to s..
PU
09/14ROYAL DSM N : DSM prefers direct sale of materials division, CEO says
RE
09/14ROYAL DSM N : Dutch DSM to exit materials to focus on food, health and climate
RE
09/14ROYAL DSM N : DSM Begins Strategic Review of Materials Businesses in Health-Focu..
MT
09/14ROYAL DSM N : DSM Targets Livestock Emission Cuts In Set of Food System Commitme..
MT
09/14ROYAL DSM N : DSM announces food system commitments to set a healthier future fo..
PU
09/14ROYAL DSM N : DSM accelerates its strategic journey to a fully focused Health, N..
PU
More news
Analyst Recommendations on ROYAL DSM N.V.
More recommendations
Financials
Sales 2021 8 957 M 10 503 M 10 503 M
Net income 2021 1 205 M 1 413 M 1 413 M
Net Debt 2021 1 095 M 1 285 M 1 285 M
P/E ratio 2021 21,1x
Yield 2021 1,38%
Capitalization 31 356 M 36 799 M 36 768 M
EV / Sales 2021 3,62x
EV / Sales 2022 3,41x
Nbr of Employees 21 173
Free-Float 91,1%
Chart ROYAL DSM N.V.
Duration : Period :
Royal DSM N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL DSM N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 183,60 €
Average target price 181,51 €
Spread / Average Target -1,14%
EPS Revisions
Managers and Directors
Dimitri de Vreeze Co-Chief Executive Officer & COO
GÚraldine Matchett Co-Chief Executive Officer & CFO
Thomas Leysen Chairman-Supervisory Board
Eileen A. Kennedy Member-Supervisory Board
Pradeep Pant Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ROYAL DSM N.V.30.40%36 968
SHIN-ETSU CHEMICAL CO., LTD.18.21%80 586
BASF SE-2.52%68 021
DUPONT DE NEMOURS, INC.-3.09%36 044
PIDILITE INDUSTRIES LIMITED33.68%16 340
ASAHI KASEI CORPORATION19.96%15 973